Anthony B. El-Khoueiry, David Balli, Jean-Frédéric Blanc, Olivier Rosmorduc, Thomas Decaens, Philippe Mathurin, Philippe Merle, Farshid Dayyani, Gianluca Masi, Tiziana Pressiani, Peter Robert Galle, Ken Hatogai, Udo Mueller, Stacey Anastasia Kalambakas, Anke Weispfenning, Yuko Ishii, Mohamed Bouattour. "Expanded biomarker analysis of an international, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.635